$ 2.23
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is neutral on EV/EBITDA.
Target Price
The average target price of IOVA is 9.4 and suggests 320% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
